StreetAlpha.app
Home › Stocks › QTTB

Q32 Bio Inc. (QTTB)

Healthcare
$8.34
▼ −1.65%
LAST CLOSE · NOV 20

Q32 Bio develops experimental antibody treatments for alopecia areata and other autoimmune and inflammatory diseases. It last closed at $8.34 on Nov 20, down 1.65% on the day. The next earnings report for QTTB is expected around Tue, Mar 9, 2027. Over its last 8 reports the stock moved an average of 5.5% the session after earnings. Over the last 12 months QTTB insiders bought $30.0M of stock on the open market and sold $505K, according to SEC Form 4 filings.

AI Auto Pilots
Is QTTB in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold QTTB.

Key Stats

Fiscal 2025
Results
Revenue
$53.7M
Net income
$29.8M
55.5% margin
EPS (diluted)
$2.42
Free cash flow
−$33.5M
−62.4% margin
Valuation
Market cap
$249.6M
29.9M shares
P/E
3.4
Price over 12 month EPS
Price to sales
4.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$289.6M
At Sep 30
Shareholder equity
$287.7M
Shares outstanding
29.9M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $34.0M$34.0MFY2021FY2022: $3.2M$3.2MFY2022FY2023: −$6.7M−$6.7MFY2023FY2024: $0$0FY2024FY2025: $53.7M$53.7MFY2025

From QTTB's SEC filings, latest 10-Q for the period ending Dec 31, 2025 (filed Nov 4).

Next report
Mar 9
Estimated date · Time not announced
Reported EPS
—
Not on file yet
Year ago EPS
—
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
How QTTB moved after its last 8 reports
Average move the session after a report ±5.5%
Nov 4, 2026Time not announced+2.4%
Aug 5, 2026Time not announced+2.1%
May 5, 2026Time not announced+2.0%
Mar 10, 2026Time not announced+17.4%
Nov 13, 2025Time not announced−9.1%
Aug 6, 2025Time not announced−1.5%
May 8, 2025Time not announced−1.9%
Mar 11, 2025Time not announced−7.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on QTTBStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on QTTB
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on QTTB

Technical Analysis

QTTB · as of the Nov 20 close · updated each morning
Turning down

The stock is 6% below its 20 day and 7% below its 50 day average. It is 15% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 41). The nearest support is the swing low (Nov 5) at $8.22, and the nearest resistance the Pivot at $8.38.

Short trendBearish
Long trendNeutral
MomentumWeak
StretchNormal
VolatilityLow, 6.7%/day
Key levels
$23.5752 week high+182.6%
$11.90100 day average+42.7%
$9.60200 day average+15.1%
$9.01Swing high (Oct 22)+8.0%
$8.9350 day average+7.1%
$8.8120 day average+5.6%
$8.55Pivot R1+2.5%
$8.38Pivot+0.5%
$8.34Last close
$8.22Swing low (Nov 5)−1.4%
$8.18Pivot S1−1.9%
$1.9152 week low−77.1%
Indicators
RSI (14)40.92Middle of its rangeNeutral
MACD-0.17Below its signal lineBearish
Stochastic23.2Middle of its rangeNeutral
ADX (14)17.5No clear trend
Williams %R-83.3Oversold below −80, overbought above −20Oversold
CCI (20)-121.7Oversold below −100, overbought above 100Oversold
Rate of change−9.8%Change over 10 sessionsBearish
ATR (14)$0.56Typical daily range, 6.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for QTTB

What happened before

See how QTTB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow QTTB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How QTTB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for QTTBHow many large options trades hit QTTB, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

QTTB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲72 buying vs 31 selling
  • ▲Held by funds +33.3 pts
  • ▲Funds holding +33
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding10572+45.8%
In funds' top 1013−66.7%
Held by funds107.5%74.2%+33.3 pts
New / increased48 / 2428 / 18+56.5%
Reduced / sold out15 / 1613 / 8+47.6%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See QTTB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

QTTB Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$30.0M2 buys · 2 insiders
Sold$505K11 sales · 3 insiders
Cluster buy: 2 insiders bought $30.0M between May 28 and May 28.
2025-12 sold $109K2026-02 sold $75K2026-05 bought $30.0M2026-08 sold $275K2026-10 sold $45KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 6Lee KalowskiCFO and PresidentSale1,301$8.32$11K
Oct 6Shelia M. VioletteChief Scientific OfficerSale917$8.32$8K
Oct 6Jodie Pope MorrisonCEOSale3,221$8.32$27K
Aug 25Shelia M. VioletteChief Scientific OfficerSale2,798$16.56$46K
Aug 25Jodie Pope MorrisonCEOSale9,845$16.56$163K
Aug 25Lee KalowskiCFO and PresidentSale3,972$16.56$66K
Every insider buy and sale for QTTB over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See QTTB insider trades →

From SEC Form 4 filings by QTTB's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether QTTB is in one of them and how their past QTTB trades turned out.

QTTB in the AI portfolios
Loading…

QTTB News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered QTTB in an article yet. Here's the latest on the wider market.

QTTB in the news

About Q32 Bio

Q32 Bio is a biotechnology company in Waltham, Massachusetts, that develops experimental biologic medicines for patients with alopecia areata, a condition that causes hair loss, and other autoimmune and inflammatory diseases. Its lead candidate, bempikibart, is an antibody designed to block two immune signals and is being tested in clinical trials. The company also holds a tissue-targeted complement inhibitor platform, which it is evaluating for strategic options.

Headquarters
Waltham, MA